

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representation of  
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

International Patent Classification <sup>6</sup> : A23C 21/00, 9/14, A23L 2/00	A1	(11) International Publication Number: <b>WO 95/10192</b>  (43) International Publication Date: 20 April 1995 (20.04.95)
(21) International Application Number: PCT/FI94/00417 (22) International Filing Date: 20 September 1994 (20.09.94) (30) Priority Data: 934494                      12 October 1993 (12.10.93)      FI (71) Applicant (for all designated States except US): VIABLE BIOPRODUCTS LTD. [FI/FI]; Tykistökatu 6. BioCity, FIN-20520 Turku (FI). (72) Inventors; and (75) Inventors/Applicants (for US only): JALONEN, Harry [FI/FI]; Hurinkatu 11 A 4, FIN-20610 Turku (FI). LUOPA, Jyrki [FI/FI]; Kapteeninpolku 4 D 14, FIN-02430 Masala (FI). AALTO, Jouni [FI/FI]; Inkoistenkatu 26 as 2, FIN-21260 Raisio (FI). (74) Agent: TURUN PATENTTI-TOIMISTO OY; P.O. Box 99, FIN-20521 Turku (FI).	(81) Designated States: AM, AT, AU, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published With international search report. With amended claims.	

(54) Title: NUTRITIONAL DRINK

(57) Abstract

The invention relates to a nutritional drink improving physical performance and recovery, based on colostrum. The product comprises a colostrum fraction obtained by separating the fat from the colostrum with a conventional method, then possibly precipitating and removing the casein of the defatted colostrum obtained in this manner, recovering the whey obtained as a filtrate and sterilizing the whey or the defatted colostrum. The sterilization is preferably carried out by microfiltration or ultrafiltration.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## NUTRITIONAL DRINK

The invention relates to a nutritional drink product based on colostrum, for the improvement of physical performance and recovery from the effects of physical exercise.

Drinks that restore the energy and fluid balance, suitable  
5 for athletes and persons occupied in strenuous physical  
labour have been prepared previously. These preparations  
usually contain mineral substances and sources of energy,  
such as different kinds of sugars. Drinks based on milk may  
be divided in three categories: drinks containing milk  
10 sugar (lactose), drinks based on the mineral substances  
contained in milk, and drinks based on the proteins  
contained in milk. In the European patent publication EP  
499165 drinks are described which contain sugars, such as  
lactose, galactose and glucose, extracted from milk. In the  
15 European patent publication EP 113898 drinks are described  
which are based on the proteins recovered from milk whey.  
In the Japanese patent application publication JP 3259070  
drinks based on the mineral substances of milk, suitable  
for athletes, are described.

20 The above-mentioned drinks, however, are mainly useful only  
as preparations restoring fluid balance and as sources of  
energy.

Especially elite athletes are handicapped by the all too  
slow recovery after physical exercise. The slow recovery is  
25 due to e.g. damage to muscle cells.

Creatine kinase (CK) is an intracellular enzyme whose  
concentration in blood increases during various muscular  
diseases. The cellular damage following sports performances  
also results in the leaking of the intracellular enzyme  
30 into the circulatory system, i.e. sports performances also  
result in increased blood CK values. Consequently, blood CK

concentration may be used as a measure of cellular damage. It has been shown in the literature (Houmard et al., Int. J. of Sports Medicine, 11(1), February 1990, pp. 41-45 and Kanter, M.M. et al., Eur. J. of Applied Physiology and Occupational Physiology, 57(1), 1988, pp. 60-63) that the blood CK concentration of athletes increases during a sports performance. Guezennec, C.Y. et al. (Science & Sports 1(3), Oct. 1986, pp. 255-263) state that increased blood CK concentration reflects the muscle cell damage observed during the period of recovery. Cade, J.R. et al. (Eur. J. of Applied Physiology 63(3/4), 1991, pp. 210-215) state that nourishment affects the increased blood CK values of athletes during the period of recovery. They concluded that ingestion of milk proteins had a beneficial effect on the recovery process in athletes as measured by CK concentration.

The preparation of cellular damage cannot be helped by adding energy and minerals to the organism. Consequently, known nutrients are ineffective in this task.

During periods of strenuous exercise, such as in training camps, an athlete endures harder than average training stress. This means that he will have insufficient time for recovery. During exercise an athlete senses an increased mental as well as physical fatigue in relation to the duration of the training camp. The quality of the exercises decreases with time spent in the training camp for the afore-mentioned reasons: the mental engagement in individual exercises decreases, and physical performance decreases faster as the exercises continue.

A surprising observation has been made lately: By administering the athletes sterilized whey of colostrum it has been possible to significantly accelerate their recovery after exercise. The said whey of colostrum has, in addition, been observed to simultaneously improve performance and the general well-being of the athletes.

The invention thus relates to a nutritional drink based on colostrum, for the improvement of physical performance and for the acceleration of the recovery process. The product comprises a colostrum fraction obtained by the separation  
5 of fat from colostrum by a conventional method, possibly by the precipitation of the casein of the defatted colostrum obtained in this manner and by the separation of the precipitated casein, as well as by the recovery of the whey obtained as a filtrate. Finally, the whey or the defatted  
10 colostrum is sterilized.

Colostrum cannot be sterilized by heat (pasteurization), because heating denatures the proteins in colostrum and coagulates it. Sterilization is done in practice by removing bacteria by microfiltration or ultrafiltration.

15 In both cases, fat must first be removed from colostrum, e.g. by filtering or by centrifuging with a conventional centrifuge or with a dairy separator. Especially in the case of sterilization by microfiltration it is advisable to remove casein from colostrum before transferring it onto  
20 the filter, because casein may easily clog the microfilter. Microfiltration usually means filtration within porosity range of 0.05  $\mu\text{m}$  - about 5  $\mu\text{m}$ . Casein may be removed by e.g. adjusting the mixture to approximately pH 4.5 by adding e.g. hydrochloric acid. Casein may alternatively be  
25 precipitated with enzymes. The resulting casein-containing precipitate may be separated from the liquid by e.g. filtering. The filtrate, which is a clear liquid, is called whey. The whey will then be neutralized to approximately pH 7.

30 A preferable method for the sterilization of whey is microfiltration. Tangential filtration with membranes of pore size 0.1 - 0.45  $\mu\text{m}$  is preferred. Prefiltration of whey with a coarse filter, e.g. a cartridge filter of about 10  $\mu\text{m}$  pore size, before transfer onto the microfilter, is

especially recommended. Better recovery is then obtained.

According to another alternative method, whey may be sterilized with an ultrafilter with a cut-off value of more than 200000 Da.

5 Yet another alternative method for sterilization is to transfer the defatted colostrum, without previous removal of casein, directly onto ultrafilter (cut-off 200000 Da). The ultrafilter also removes the casein. Casein will cause no technical problems in this method, because casein  
10 molecules, due to their size, which is considerably larger than the pores of the filter, do not clog the filter.

It is unnecessary and inadvisable to use filters with smaller pore size, because then a large part of beneficial immunoglobulins would also be removed.

15 Suitable additives such as preservatives, lactase or flavouring may further be added to the sterilized product. A lemon flavouring gives whey a pleasant smell and taste. The function of added lactase is mainly to break down lactose, and it makes the said product suitable for persons  
20 suffering from lactose intolerance. In addition, added lactase has been observed to improve the taste of the said product.

The invention will be illustrated with the following examples, and the results illustrating the potency of the  
25 preparation will be shown in the following figures, in which

Figure 1 shows the creatine kinase values (IU/ml) of a group of athletes consuming colostrum whey (filled squares) and of a control group (open squares), measured in the  
30 morning, during the first camp

Figure 2 shows the creatine kinase values (IU/ml) of a

5

group of athletes consuming colostrum whey (filled squares) and of a control group (open squares), measured in the evening, during the first camp

Figure 3 shows the creatine kinase values (IU/ml) of a group of athletes consuming colostrum whey (filled squares) and of a control group (open squares), measured in the morning, during the second camp

Figure 4 shows the creatine kinase values (IU/ml) of a group of athletes consuming colostrum whey (filled squares) and of a control group (open squares), measured in the evening, during the second camp

Figure 5 shows the time (s) required by a group of athletes consuming colostrum whey (filled columns) and of a control group (open columns), for skiing 1.5 kilometers on roller-skis at the beginning and the end of the first camp

Figure 6 shows the increase in creatine kinase values (IU/ml) of a group of athletes consuming colostrum whey (filled columns) and of a control group (open columns) at the end of a roller-ski test (1) and a running test (2) during the first camp

#### Example 1

##### a) preparation of colostrum whey

Frozen colostrum obtained from the 1st - 5th milking was thawed. The thawed colostrum was defatted with a conventional dairy separator. Casein was precipitated from the defatted colostrum with hydrochloric acid. The precipitate was separated from the whey with a sieve. The whey recovered was frozen.

##### b) sterilization of colostrum whey



6

The whey obtained in step a) was filtered with a tangential microfiltration membrane of pore size 0.1  $\mu\text{m}$ . Commercial lactase preparation was added to the sterilized whey at 0.05% (v/v).

5 Example 2

The whey of Example 1 was filtered with a tangential microfiltration membrane of 0.22  $\mu\text{m}$  pore size. Commercial lactase preparation was added to the sterilized whey at 0.05% (v/v).

10 Example 3

The whey of Example 1 was prefiltered through a 10  $\mu\text{m}$  cartridge filter. The whey was then filtered with a tangential microfiltration membrane of 0.22  $\mu\text{m}$  pore size. Commercial lactase preparation was added to the sterilized whey at 0.05% (v/v).

Example 4

The whey of Example 1 was filtered with a tangential microfiltration membrane of 0.45  $\mu\text{m}$  pore size. Commercial lactase preparation was added to the sterilized whey at 0.05% (v/v).

Example 5

The defatted colostrum prepared in Example 1 was filtered with a tangential ultrafiltration membrane with 300000 Da cut-off value. Commercial lactase preparation was added to the sterilized whey at 0.05% (v/v).

Colostrum whey sterilized according to Example 1 was used in tests with athletes, which tests are described in the following section.

The efficiency of the nutritional drink based on the said invention was tested during two different training camp periods. The differences in recovery, performance and general well-being of athletes consuming colostrum whey and those consuming ordinary milk whey were evaluated and compared.

The tests were carried out as cross-over tests during two consecutive training camps. Eight elite skiers participated in both camps (athletes A - H). The skiers were distributed in two groups (four skiers per group). During the first camp skiers A - D constituted the group consuming colostrum whey while skiers E - H constituted the group consuming ordinary milk whey (the control group). The dose for each group was 600 ml per day and per person. During the second camp the skiers A - D constituted the control group consuming ordinary milk whey while skiers E - H constituted the group consuming colostrum whey. The test skiers did not know whether they consumed colostrum whey or ordinary milk whey.

Ordinary cross-country skiing on the one hand and roller-skiing and running on the other hand were in the program of the camps. Both groups followed the same training program. During both camps, the creatine kinase values of the athletes were obtained in the mornings and in the evenings during seven days. The performances of each group were also evaluated in the roller-ski as well as the running tests.

Figures 1 - 4 show that the creatine kinase values of the athlete group consuming colostrum whey (filled squares) were lower than the creatine kinase values of the control group consuming ordinary milk whey (open squares). This is a clear indication of the beneficial effect of colostrum whey on the recovery of the athlete. The decline in CK value in the control group after the sixth day, seen in Figure 1, was due to the fact that the group was unable to carry out all the exercises of the period according to

plan, and was forced to cut down their exercises.

Figure 5 shows that the performance of both groups of athletes in the roller-ski test (measured by the time in seconds needed for skiing 1.5 km) improves from the beginning to the end of the training camp. The values measured for the group consuming colostrum whey (filled columns), however, are better than the values for the control group consuming ordinary milk whey (open columns). This allows the conclusion that colostrum whey has a beneficial effect also on physical performance.

Figure 6 shows that the creatine kinase values of both groups of athletes increase after the roller-ski test (1) as well as after the running test (2). The increase in the CK values of the group of athletes consuming colostrum whey (filled columns), after both kinds of exercise is, however, considerably smaller than the increase in the values of creatine kinase of the control group consuming ordinary milk whey (open columns).

It should be understood that the sterilized colostrum whey products presented here as examples are intended to illustrate the invention and not to restrict its scope of application. A specialist in the field will appreciate that the different applications of the said invention may vary within the scope of the claims to be presented in the following section.

## CLAIMS

1. A nutritional drink improving physical performance and recovery, based on colostrum, characterized in that it comprises a colostrum fraction obtained by
  - defatting the colostrum with a conventional method,
  - 5 - optionally precipitating the casein contained in the defatted colostrum obtained by the above method, separating the precipitated casein, and recovering the whey obtained as filtrate, and
  - sterilizing the whey or defatted colostrum.
- 10 2. The product according to Claim 1 characterized in that the whey from which casein has been removed, has been sterilized by microfiltration.
3. The product according to Claim 2 characterized in that the whey has been prefiltered with a coarser filter before  
15 microfiltration.
4. The product according to Claim 1 characterized in that the whey or defatted milk has been sterilized by ultrafiltration with a filter with a molecular size cut-off of more than 200000 Da.
- 20 5. The product according to any one of the Claims 1 - 4 characterized in that it further comprises preservatives, lactase or flavouring.
6. The product according to Claim 5 characterized in that it further comprises a commercial lactase preparation to  
25 about 0.05% (v/v) of the sterilized product.

## AMENDED CLAIMS

[received by the International Bureau on 07 February 1995 (07.02.95); original claims 2 and 4 cancelled; original claim 1 amended; original claims 3, 5 and 6 unchanged but renumbered as claims 2, 3 and 4 (1 page)]

1. A nutritional drink improving physical performance and recovery, based on colostrum, characterized in that it comprises a colostrum fraction obtained by defatting the colostrum with a conventional method, and either
  - 5 i) precipitating the casein contained in the defatted colostrum obtained by the above method, separating the precipitated casein, recovering the whey obtained as filtrate, and sterilizing the whey either by microfiltration or by ultrafiltration with a filter with a  
10 molecular size cut-off of more than 200000 Da, or
  - ii) sterilizing the defatted colostrum by by ultrafiltration with a filter with a molecular size cut-off of more than 200000 Da.
2. The product according to Claim 1 characterized in that  
15 the whey has been prefiltered with a coarser filter before microfiltration.
3. The product according to Claim 1 or 2 characterized in that it further comprises preservatives, lactase or flavouring.
- 20 4. The product according to Claim 3 characterized in that it further comprises a commercial lactase preparation to about 0.05% (v/v) of the sterilized product.

1/6




Fig.1




Fig.2




Fig. 3






Fig. 4




Fig. 5

6/6




Fig. 6

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI 94/00417

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: A23C 21/00, A23C 9/14, A23L 2/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A23C, A23L		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
DIALINDEX, WPI, CLAIMS/US PATENTS, JAPIO, CAB ABSTRACTS, FOOD SCI. & TECH. ABS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A1, 0471890 (BIOTEST PHARMA GMBH), 26 February 1992 (26.02.92), column 1, line 51 - column 2, line 6 --	1,4
X	US, A, 4051235 (R.R. PLYMATE), 27 Sept 1977 (27.09.77), claim 1 --	1,4
X	GB, A, 1573995 (SOCIETE DES PRODUITS NESTLE S.A.), 3 Sept 1980 (03.09.80), claims 1-2 --	1,4
X	WO, A1, 9308264 (VALIO BIOPRODUCTS LTD. ET AL.), 29 April 1993 (29.04.93), page 8, line 33 - page 9, line 4 --	1
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search		Date of mailing of the international search report
13 January 1995		25 -01- 1995
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  INGA-KARIN PETERSSON Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 94/00417

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB, A, 1211876 (TWYFORD LABORATORIES LIMITED), 11 November 1970 (11.11.70), page 3, line 54 - line 93, claim 1  ---	1
A	EP, A2, 0173999 (BIOTEST PHARMA GMBH), 12 March 1986 (12.03.86), claims 1,10  -- -----	1-6

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

26/11/94

International application No.

PCT/FI 94/00417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0471890	26/02/92	DE-A, C- 4026365 DE-D- 59007518 JP-A- 6121637 US-A- 5147548	27/02/92 00/00/00 06/05/94 15/09/92
US-A- 4051235	27/09/77	NONE	
GB-A- 1573995	03/09/80	AU-B- 519091 AU-A- 3490378 CA-A- 1101333 CH-A- 627079 DE-A, C- 2813984 FR-A, B- 2387039 JP-C- 1496238 JP-A- 53130411 JP-B- 63040771 NL-A- 7804015 OA-A- 5938 SE-B, C- 448062 SE-A- 7804190	05/11/81 18/10/79 19/05/81 31/12/81 26/10/78 10/11/78 16/05/89 14/11/78 12/08/88 17/10/78 30/06/81 19/01/87 16/10/78
WO-A1- 9308264	29/04/93	AU-A- 2666792 CA-A- 2121472 EP-A- 0610245 FI-C- 91166 NZ-A- 244731	21/05/93 29/04/93 17/08/94 25/05/94 26/07/94
GB-A- 1211876	11/11/70	DE-A- 1810438	10/07/69
EP-A2- 0173999	12/03/86	SE-T3- 0173999 DE-C- 3432718 JP-C- 1768852 JP-B- 4057649 JP-A- 61068429 US-A- 4644056	22/05/86 30/06/93 14/09/92 08/04/86 17/02/87

Form PCT/ISA/210 (patent family annex) (July 1992)